Clinical trial
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid Tumors
NCT01722825 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid Tumors
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2012
- Completion date
- June 30, 2014
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.